Recent advances in the development of EGFR/Src, Src/Abl, EGFR/VEGFR2, EGFR/c-Met, STAT-3/c-Src, VGERF/FAK and EGFR/HER dual-targeted kinase inhibitors
{{output}}
Introduction: Although several therapies have been applied for cancer treatment and mutations, drug resistance remains a significant impediment to the efficient use of single-therapy. Multi-targeting therapies are designed to com... ...
